LEVEL's Sleep Protab Sees Notable Results in Real-World Study
Here comes a curveball from the realm of sleep aids: LEVEL's Sleep Protab just dropped some intriguing results from a real-world 29-day study, shaking up the sleep enhancement scene with its cannabinoid cocktail. Ain't it something when a mix of CBD, CBG, and CBN can eke out an extra 41 minutes of shut-eye on average? Not just those inevitable minutes, but participants also felt like they'd seen the sunrise on the right side, reporting a refreshing 227% jump in next-morning clarity. That's a wake-up call for anyone underestimating the power of cannabinoids in the pursuit of decent Zs.
Breaking Down The Findings
The gritty numbers tell the tale: 157 participants willingly tested these waters, offering their sleep patterns to science. MoreBetter, an independent research firm, helped tally the changes. Participants not only clocked more snooze time but also improved in ways that aren't typically easy to measure. Here's what went down:
- Average sleep time increased by 27 minutes through the product-use phase, topping off at a full 41 minutes by the study's end.
- A probability shift from 19.39% to 63.44% in waking up refreshed—imagine feeling like a million bucks 227% more often!
- Slept like babies? Maybe not, but a 25% drop in nightly awakenings says something was brewing.
- Say goodbye to the morning-after haze; only 7.6% reported any hangover effects post-use.
- Not just sleep, but well-being zoomed up by nearly 12 points on the WHO-5 Well-Being Index. That's shooting from "poor" to "good" within a month.
The Big Sleep Conundrum
But don't roll out the red carpet just yet. Sleep aids, especially those from the hemp world, face a lot of skepticism due to a lack of rigorous testing and often fall flat in real-world scenarios. LEVEL's effort to put its Sleep Protab under the scrutinizing light of this real-world study is a big step. Unlike others banking on ingredient-level drop-per-drop insights, LEVEL's looking at the complete formulation picture. Their CEO, Chris Emerson, PhD, underscored that it's all about consistency over dosage—not the one-off magic pill but a cumulative effect when used over time.
The hemp category has a research deficit, and consumers know it. The burden is on brands to do the work and publish the results, even when findings are uncomfortable.
What's Next for LEVEL?
From a product lineup including various Protabs and Tablinguals, LEVEL's making noise with precision cannabinomics, trying to pivot from skepticism towards credibility. More impressive perhaps is how this feeds into their aim: achieving predictable results across sleep, calm, focus, and recovery. Cannabinoid fans can start small with a $20 Discovery Kit—an enticing gateway to trying the efficacy firsthand.
LEVEL isn’t just dabbling in sleep aids; it's trying to mold itself into a science-forward powerhouse, one formulation at a time. The results of this study give them some street cred, if not a complete green light, to push deeper into regulated markets with a slew of sleep, calm, and focus products. With patent-backed promises and a confident foot in the cannabinoid world, they're aiming higher with every snooze they enhance.
The Road to Credibility
The results here substantiate LEVEL’s push in bridging a troublesome gap in clinical evidence for hemp-based consumer products. With MoreBetter lending its research prowess to this study, the data not only enhances the reputation of LEVEL but challenges rivals to show up with equally rigorous proofs of competence.
Bottom line, LEVEL has tapped into something folks stand to watch: a potential market disruptor that might make it mainstream if it continues proving itself through robust scientific validation. This study is a reminder that sometimes, it's not just about what's in the bottle but whether you can back it up with real-world evidence. Investors, take note.
